By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Lightlake Therapeutics Inc. 

London      United Kingdom
Phone: n/a Fax:


Company News
Lightlake Therapeutics Inc. (LLTP) March 5th Presentation At Now Available For On-Demand Viewing 3/9/2015 10:35:19 AM
Lightlake Therapeutics Inc. (LLTP), Licensor Of A Treatment To Reverse Opioid Overdoses, To Webcast Live, At March 5th 2/27/2015 10:32:03 AM
Lightlake Therapeutics Inc. (LLTP) Announces Fast Track Designation From The United States FDA For Intranasal Naloxone Treatment To Reverse Opioid Overdose 2/17/2015 11:47:12 AM
Lightlake Therapeutics Inc. (LLTP) Announces Arvind Agrawal Appointed Executive Vice President, Medical Affairs 2/9/2015 10:06:28 AM
Lightlake Therapeutics Inc. (LLTP), Adapt Pharma Forge Deal Worth $55 Million 12/16/2014 9:17:03 AM
Lightlake Therapeutics Inc. (LLTP) Commences Trial For Treatment Of Opioid Overdose With The U.S. National Institute On Drug Abuse (NIDA) 12/4/2014 11:04:21 AM
Lightlake Therapeutics Inc. (LLTP) Announces Closing Of Investments In Two Products 10/2/2014 9:19:22 AM
Lightlake Therapeutics Inc. (LLTP) Receives Funding Commitment From A Prominent International Research And Development Foundation 7/30/2014 8:31:26 AM
Lightlake Therapeutics Inc. (LLTP) Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 7/23/2014 12:00:10 PM
Lightlake Therapeutics Inc. (LLTP) Signs Agreement With Commercial Contract Manufacturer For Its Opioid Overdose Reversal Treatment 7/9/2014 9:54:15 AM